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ABSTRACT
 يف  نيدوريتوسيف  و  ينسانيفيلوس  مادختسا  ةنراقلم   :فادهلأا
.)OAB( ةناثلما طاشن طرف جلاع
 نيذلا  ىضرلما  يف  ةيلبقتسلما  ةساردلا  هذه  تيرجأ   :ةقيرطلا
 ءاسنلا  ضارمأ  مسقل  رضح  نيذلاو  OAB  مهتباصإ  تصخش
 مامإوشتوس ةعماج ،بطلا ةيلك ،ةيلوبلا كلاسلما ةحارجو ديلوتلاو
 م2013  ربوتكأ  ينب  ام  ةرتفلا  للاخ  ايكرت  ،نامرهك  ،نامرهك
 1  ةعومجلما  .ينتعومجم  ىلإ  ىضرلما  مسُق  .م2014  سطسغأو
 تقلت  ينح  يف  ،ًايموي  ينسانيفيلوس  غلم  5  تقلت  )n = 60(
 تلجسو  .ًايموي  نيدوريتوسيف  غلم  n = 59( 4(  2  ةعومجلما
 يف   )OABSS( مادختساب OAB ىضرلما عيمج ضارعأ جئاتن
 فيلاكت  مييقت  تم  ،كلذ  ىلإ  ةفاضلإاب  .12  و  4  و  0  عيباسلأا
.ةيودلأل ةيبنالجا راثلآاو جلاعلا
 9.5 :يلاتلا وحنلا ىلع )1 ةجرد( OABSS ديدتح تم  :جئاتنلا
 ؛0  عوبسلأا يف 2  ةعومجلما  1.8 ±  10.7  و  1  ةعومجلما 2.8 ±
 يف  )2  ةعومجلما(  1.3  ±  2.4  و  )1  ةعومجلما(  1.2  ±  2.2
 0.6 ± 1.3 و 1 ةعومجلما 0.5 ± 1.3 و ؛)2 ةجيتنلا( 4 عوبسلأا
 لا ،كلذ ىلإ ةفاضلإابو .)طاقن 3( 12 عوبسلأا يف 2 ةعومجلما
 ةجرد( p = 0.062( تاجرد ينب ريبك يئاصحإ فلاتخا دجوي
 ناك  .)3  ةجرد( p = 0.527و ،)2  ةجرد( p = 0.464  ،)1
 نع  )0%(  0  ةيبنالجا  اهراثآ  ببسب  ءاودلا  نع  فقوتلا  لدعم
 تاريغتلا تناكو .2 ةعومجلما نع )10.2%( 6 و ،1 ةعومجلما
 ةللاد تاذ ميقلا 2-3 و ،1-3 ،1-2 جئاتنلا يف ةعومجلما لخاد
.)p <0.001( ينتعومجلما نم لك يف ةيئاصحإ
 نم ينعونلا نيذه نم OABSS ينب ريبك قرف دجوي لا  :ةتمالخا
 ببسب ةيودلأا  مادختسا نع فقوتلا ناك ،كلذ عمو  .ةيودلأا
.نيدوريتوسيف يف ًارتاوت رثكأ ةيبنالجا راثلآا
Objectives: To compare the use of solifenacin and 
fesoterodine in treatment of overactive bladder 
(OAB). 
Methods: This prospective study was conducted on 
patients diagnosed with OAB who presenting to 
the Department of Obstetrics and Gynecology and 
Urology, School of Medicine, Kahramanmaraş Sütçü 
İmam University, Kahramanmaraş, Turkey between 
October 2013 and August 2014. Patients were 
randomized into 2 groups. Group 1 (n=60) received 
5 mg solifenacin per day, while Group 2 (n=59) 
received 4 mg fesoterodine per day. All the patients’ 
OAB symptom scores (OABSS) in weeks 0, 4, and 12 
were recorded. In addition, treatment costs and side 
effects of the drugs were evaluated.
Results: Average OABSS (score 1) was determined as: 
9.5 ± 2.8 for Group 1 and 10.7 ± 1.8 for Group 2 at 
week 0; 2.2 ± 1.2 (Group 1) and 2.4 ± 1.3 (Group 
2) at week 4 (score 2); and 1.3 ± 0.5 for Group 1 
and 1.3 ± 0.6 for Group 2 at week 12 (score 3). In 
addition, no statistically significant difference was 
found between the scores (p=0.062 (score 1), p=0.464 
(score 2), and p=0.527 (score 3). The discontinuation 
rate of medication due to its side effects was 0 (0%) 
for Group 1, and 6 (10.2%) for Group 2. Intragroup 
changes in the scores 1-2, 1-3, and 2-3 values was 
statistically significant in both groups (p<0.001).
Conclusion: No significant difference was found 
between the OABSS of these 2 drugs. However, 
discontinuation of drugs due to side effects was more 
frequent in fesoterodine.
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Overactive bladder (OAB) has been defined by the International Continence Society as urgency, 
frequency, and nocturia no matter whether it is urge 
incontinence or not, and as a condition, in which other 
pathological and metabolic factors that may cause those 
situations are excluded.1 While 85% of OAB patients 
were diagnosed with urge incontinence, 90% of them 
have urgency, frequency, and nocturia.2 In the United 
States, OAB affects approximately 33 million people.3 
Prevalence of this disorder in the over 18-year-olds 
general population in Europe is similar in men and 
women, at a rate of 11.8%.4 The prevalence of OAB 
increases with aging in both genders, and this rate is 
approximately 30% in women over the age of 65.5 
Overactive bladder causes significant impairment in 
an individuals’ physical, social, emotional, and sexual 
functions. Therefore, its treatment is quite important, 
as it reduces the quality of life for patients.6 Various 
methods for treatment of OAB is used, such as 
behavior training, medical, and surgical treatment. In 
the pharmacological treatment of OAB, particularly 
anticholinergics (solifenacin, tolterodine, fesoterodine, 
trospium, darifenacin, propantheline), Ca channel 
blockers, antidepressants (duloxetine, imipramine), 
α-adrenergic receptor antagonists (doxazosin, prazosin, 
tamsulosin, terazosin) β-adrenergic receptor agonists 
(mirabegron, albuterol, terbutaline), cyclooxygenase 
(COX inhibitors) (indomethacin, flurbiprofen) toxin 
and mix effective drugs (oxybutynin, propiverine, 
baclofen, and so forth) are used.7,8 While there are 
a lot of studies in the literature, which compare 
the effectiveness of drugs in the treatment of OAB, 
there is no study, which examines solifenacin and 
fesoterodine that are relatively new drugs. Although 
a study comparing solifenacin and tolterodine, which 
is the active metabolite of fesoterodine was published 
in 2014, there is no study in the literature, which 
compares solifenacin and fesoterodine.9 Taking effect 
through substantially and rapidly converting into active 
metabolite 5-hydroxymethyl tolterodine (5-HMT) 
by nonspecific esterase, fesoterodine was approved by 
the European Medicines Agency in 2007.10,11 On the 
other hand, solifenacin which has a greater selectivity 
for the bladder M3 receptor, and is distinguished with 
the ability of long-term effectiveness, and reducing 
urge attacks was approved by the European Medicines 
Agency in 2004.12,13 In this study, we aim to compare 
the effectiveness of these 2 drugs in the treatment of 
OAB, the use of which has started in recent years. 
Methods. The study protocol has been prospectively 
prepared and submitted to, and approved by the Local 
Ethics Committee in Kahramanmaraş, Turkey. This 
work was undertaken and conforms with the provisions 
of the Helsinki Declaration. Patients who presented 
to the Department of Obstetrics and Gynecology and 
Urology at the School of Medicine, Kahramanmaraş 
Sütçü İmam University, Kahramanmaraş, Turkey 
between October 2013 and August 2014 with disorder 
of urinary incontinence, and with frequency of urination 
of ≥8/day and urgency of ≥1/day, and diagnosed with 
OAB were included in the study. Patients using alpha 
blockers or 5-alpha reductase inhibitors, or having used 
them in the previous 2 months, those who experienced 
pelvic surgery (hysterectomy, suspended operations, 
and so forth), and received OAB treatment with 
antimuscarinics within the previous 3 months, and 
have been through co-morbidities, such as neurogenic 
bladder, diabetes, and those with the history of 
acute urinary retention, predominant stress urinary 
incontinence, and pelvic organ prolapse that require 
catheterization, or those who experienced lower urinary 
tract surgery within the last 6 months were excluded 
from the study. At the beginning of the study, patients 
who met the inclusion criteria were randomly divided 
into 2 groups using a web-based randomization software 
(www.randimizer.org). Our power value for an effect 
size of 0.88 calculated with α=0.05, n=60 (Group 1), 
n=59 (Group 2) was found as 0.99 (99%) in the post 
power analysis carried out when the total number of 
the patients reached to 119, the study was terminated 
due to the number of samples was considered sufficient 
statistically. With the diagnosis of OAB, Group 1 
(n=60) received 5 mg solifenacin per day while Group 2 
(n=59) received 4 mg fesoterodine per day. All patients’ 
OAB symptom scores (OABSS) for the beginning week 
(0), week 4, and week 12 were recorded. The maximum 
score for intraday frequency was 2, night frequency was 
3, urgency was 5, and urgency incontinence was 5.14 
Besides the side-effects that occurred in both groups, 
the rate of discontinuation of the treatment were 
recorded. Finally, monthly drug costs were calculated 
for both groups. After the study, follow-ups of patient’s 
who left treatment due to side effects were continued in 
our clinic. 
Disclosure. Authors have no conflict of interests, and the 
work was not supported or funded by any drug company.
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Statistical analysis was performed using the Statistical 
Package for Social Sciences version 20 (IBM 
Corporation, Armonk, NY, USA). Quantitative data 
were expressed as mean ± SD (standard deviation) in 
tables. In analyzing data, the values of average, frequency, 
and SD were identified. To demonstrate the differences 
between the 2 groups, Student-t and Mann-Whitney U 
test was used. Matched t-test was applied to determine 
the change in OABSS values. Data were analyzed with 
95% confidence interval and statistical significance 
was determined at p>0.05. Post power analysis was 
performed in order to determine the sufficient number 
of patients that will be enrolled in the study.
Results. Sixty patients in Group 1 and 59 patients 
in Group 2 were included in the study. The average age 
of patients was determined as 58.9 for Group 1, and 
58.1 for Group 2. The average age of both groups was 
similar (p=0.759). In Group 1, 45% of women and 
44% of women in Group 2 were aged 65 years and 
above. Participants involved in both groups consisted of 
patients in the similar age range (p=0.919). Demographic 
characteristics of patients are given in Table 1. No 
statistical significant difference was observed in OABSS 
values of the groups at 0, 4, and 12 weeks (Table 2). In 
addition, the score of these groups for week 0 (score 1), 
4 (score 2), and 12 (score 3) was evaluated. Changes 
in the intragroup scores 1-2, 1-3, and 2-3 values was 
statistically significant in both groups (p<0.001) (Table 
3). During the study period, dry mouth was observed 
in 3 (Group 1), and 8 (Group 2) patients. Constipation 
was observed in 1.7% in Group 1, and 5.1% in Group 
2. The total number of patients with complaints was 4 
in Group 1, and 11 in Group 2. The discontinuation 
of drugs due to side effects was of 0 in Group 1, and 6 
in Group 2, and it was significantly more common in 
Group 2 (p=0.013) (Table 4). The monthly drug costs 
of patients who received solifenacin and fesoterodine 
were determined as US$21 in Group 1, and US$34 in 
Group 2.
Discussion. Storage and urination function 
of the bladder depends on the interaction between 
parasympathetic, sympathetic, physical, and sensory 
nerves.15 Parasympathetic nerves  trigger the contraction 
of the bladder detrusor muscle through stimulation of 
M2 and M3 muscarinic receptors by acetylcholine, 
and of purinergic receptors (P2X1) by adenosine 
triphosphate, and it also relax the urethral smooth 
muscles by nitric oxide action. When compared with 
M3 receptors (20%) in the bladder, the M2 receptors 
(80%) have more expression. However, it was shown 
that the detrusor contraction is substantially carried out 
through the M3 receptor.7 The major M3 subtype that 
mediates for bladder contractions is also included in 
the salivary gland, stomach smooth muscle, and ciliary 
and iris sphincter muscles, and the blockade of this 
receptor results in anti-cholinergic side-effects, such as 
dry mouth, constipation, and blurred vision.
The OAB is a pathology that significantly affects 
the quality of life, and also leads to a sense of shame 
Table 1 - Demographic characteristics of the groups.
Characteristics Group 1 
Solifenacin
Group 2 
Fesoterodine
P-value
Age, years*   58.9 ± 11.5   58.1 ± 10.2 0.759
Gravidity† 3 (5-1) 3 (6-1) 0.856
Parity† 2 (4-1) 3 (4-1) 0.244
Body mass index, kg/m2 * 27.4 ± 5.1 26.8 ± 7.4 0.659
Duration of onset of OAB 
symptoms, months*
16 ± 5 18 ± 4 0.722
*mean ± standard deviation, †median range (maximum-minimum). 
OAB - overactive bladder 
Table 2 -  The  OABSS of the group according to weeks. 
Weeks Group 1 
Solifenacin
Group 2 
Fesoterodine
P-value
0 9.5 ± 2.8 10.7 ± 1.8 0.062
4 2.2 ± 1.2 2.4 ± 1.3 0.464
12 1.3 ± 0.5 1.3 ± 0.6 0.527
OABSS - over active bladder symptom scores
Table 3 - Difference within 2 groups in terms of the values of score 1-2, 
1-3, and 2-3. 
Scores Group 1 
Solifenacin
P-value,
Group 1
Group 2 
Fesoterodine
P-value
Group 2
Score 1-Score 2 9.5±2.8 / 2.2±1.2 <0.001 10.7±1.8 / 2.4±1.3 <0.001
Score 1-Score 3 9.5±2.8 / 1.3±0.5 <0.001 10.7±1.8 / 1.3±0.6 <0.001
Score 2-Score 3 2.2±1.2 / 1.3±0.5 <0.001 2.4±1.3 / 1.3±0.6 <0.001
Score 1 - 0 week over active bladder symptom scores (OABSS),
Score 2 - 4 week OABSS, Score 3 - 12 week OABSS
Table 4 - Incidence of drug-related side effects in both groups. 
Side effects Group 1 
Solifenacin
Group 2 
Fesoterodine
P-value
Dry mouth 3 (5.0)   8 (13.6) 0.186
Constipation 1 (1.7)   3   (5.1) 0.256
Total 4 (6.7) 11 (18.6) 0.144
Drug stop 0 (0.0)   6 (10.2) 0.013
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and anxiety in patients. People can usually take extreme 
measures to reduce urinary frequency and incontinence 
attacks, which substantially affect physical health, 
vitality, social life, emotional state, and functionality.16
Various antimuscarinics, such as oxybutynin, 
propiverine, tolterodine, trospium chloride, 
fesoterodine, and solifenacin were used in the 
treatment of OAB, and they have been widely used 
with their proven effectiveness and stability.17 The 
main basis of the use of anticholinergic agents is the 
blockage of the muscarinic M3 receptors in the bladder 
smooth muscle.18 Although there is a clinical utility 
of anticholinergics for OAB patients, it is not clear, 
which drug is more effective.19 There are some works in 
literature that evaluate the efficacy of fesoterodine and 
solifenacin, which have become prominent in recent 
years. In a review article that compared fesoterodine 
and tolterodine, it has been reported that fesoterodine 
is superior to tolterodine due to its OAB symptoms. 
However, the rate of discontinuation of the drug 
due to side effects is more common in fesoterodine 
rather than tolterodine.20 Although in their study for 
comparison of fesoterodine and tolterodine, Du Beau 
et al21 found out that both drugs are similar in terms 
of efficacy, dry mouth and constipation symptoms were 
more commonly observed in the fesoterodine group. 
A study in which placebo and fesoterodine have been 
compared in patients that gave sub-optimal response to 
the tolterodine, puts forward that treatment efficacy of 
fesoterodine is fair, and can be well-tolerated in terms of 
anticholinergic side effects.22
In the literature, 4 mg/day was proposed for 
fesoterodine as a starting dose, and the maximum 
dose was reported as 8 mg/day. However, an increase 
in anticholinergic side effects was observed along with 
increased doses.7 In a meta-analysis that included 1805 
patients and comparison of solifenacin and tolterodine 
by Liu et al9 solifenacin was found to be superior in 
terms of OAB symptoms. However, constipation 
was more frequent in those using solifenacin. No 
statistically significant difference was observed between 
them in terms of other side effects. In a study that 
compared solifenacin and oxybutynin, solifenacin 
has been found to be very effective in terms of OAB 
symptoms.23 In another study that compared solifenacin 
and tolterodine, the efficacy levels of those drugs were 
found to be similar, and anticholinergic side effects were 
substantially less common in the solifenacin group.24 
While the initial treatment dose for solifenacin is 5 mg/
day, the maximum dose may be increased to 10 mg/day. 
Although the increase in dose also means an increase 
in the efficacy of the drug, the side effects, such as dry 
mouth also substantially increases.7 However, in the 
literature, there is no study in which those drugs have 
been compared. In our study, we examined the efficacy 
of both drugs within themselves, and with each other.
A significant difference was found between the 
OABSS values of both drugs at weeks 0, 4, and 12. 
This demonstrates the effectiveness of both drugs in 
the treatment of OAB. Furthermore, this significant 
difference between OABSS values of patients in weeks 
4 and 12 shows that the pharmaceutical activity for 
the first 3 months is proportional to the lifetime of 
those drugs. This demonstrates the importance of 
continuation of using drugs (Table 3). No significant 
difference was observed in the OABSS values of both 
drugs in weeks 0, 4, and 12. These results indicate 
that these 2 preparations have similar effects (Table 
2). Due to the side effects of anticholinergic drugs, 
such as dry mouth, constipation, and blurred vision, 
the patients do not follow the treatment.25 In a study 
based on prescription data in the United Kingdom, 
the rate of discontinuation of the drugs is ranges 
between 65% and 86% in 12 months for OAB patients 
using antimuscarinics.26 The most common cause of 
discontinuation of treatment is dryness of the mouth.27 
While evaluating the side effects in our study, it was 
found out that the discontinuation of drugs due to 
the side effects was more common in treatment with 
fesoterodine, while the use of both drugs did not cause 
a significant difference for patients with dry mouth and 
constipation symptoms (Table 4). Besides, the cost of 
one-month treatment in our country was determined as 
US$21 for solifenacin, and S$34 for fesoterodine.
The main points of our study that can be criticized 
are the relatively small number of cases, and lack of 
the placebo control group. Furthermore, another 
limitation of this study was the lack of examinations 
in various drug doses. The OABSS being a scoring 
system, which is not recognized in all countries, was 
another limitation. As a result, while OABSS values of 
solifenacin and fesoterodine in the treatment of OAB 
were similar, and the positive effects of both drugs seem 
to increase with an increase in the duration of treatment. 
Discontinuation of the drug due to side effects was 
more frequent in fesoterodine. Therefore, the use of 
solifenacin for patients with the diagnosis of OAB seems 
more reasonable. Further studies will be conducted 
in the future with different doses of solifenacin and 
fesoterodine in longer treatment periods, and with 
greater number of patients are needed.
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